Pharmacodynamic responses to DNA methyltransferase inhibition

Elizabeth Griffiths, Richard L. Momparler, Adam R Karpf

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The DNA methyltransferase inhibitors, 5-azacytidine and decitabine, were initially developed at high dose for clinical use as classical cytotoxic agents and only later reidentified as epigenetically active drugs capable of reexpressing genes silenced by DNA methylation. Their clinical activity in myeloid malignancy has resulted in rapid acceptance into clinical practice for the treatment of patients with MDS and AML, a group of patients for whom other treatment strategies have been largely ineffective. Despite widespread clinical use in these patients, the mechanisms responsible for their efficacy remain opaque, and controversy remains regarding the relative contributions of demethylation of silenced tumor suppressor genes with induction of apoptosis and differentiation, induction of CG antigens expression with resultant antitumor immunity, and DNA damage events.

Original languageEnglish (US)
Title of host publicationEpigenetic Therapy of Cancer
Subtitle of host publicationPreclinical Models and Treatment Approaches
PublisherSpringer-Verlag Berlin Heidelberg
Pages171-188
Number of pages18
Volume9783642384042
ISBN (Electronic)9783642384042
ISBN (Print)364238403X, 9783642384035
DOIs
StatePublished - Apr 1 2014

Fingerprint

Methyltransferases
decitabine
DNA
Azacitidine
Cytotoxins
DNA Methylation
Tumor Suppressor Genes
DNA Damage
Immunity
Apoptosis
Antigens
Therapeutics
Pharmaceutical Preparations
Genes
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Griffiths, E., Momparler, R. L., & Karpf, A. R. (2014). Pharmacodynamic responses to DNA methyltransferase inhibition. In Epigenetic Therapy of Cancer: Preclinical Models and Treatment Approaches (Vol. 9783642384042, pp. 171-188). Springer-Verlag Berlin Heidelberg. https://doi.org/10.1007/978-3-642-38404-2_8

Pharmacodynamic responses to DNA methyltransferase inhibition. / Griffiths, Elizabeth; Momparler, Richard L.; Karpf, Adam R.

Epigenetic Therapy of Cancer: Preclinical Models and Treatment Approaches. Vol. 9783642384042 Springer-Verlag Berlin Heidelberg, 2014. p. 171-188.

Research output: Chapter in Book/Report/Conference proceedingChapter

Griffiths, E, Momparler, RL & Karpf, AR 2014, Pharmacodynamic responses to DNA methyltransferase inhibition. in Epigenetic Therapy of Cancer: Preclinical Models and Treatment Approaches. vol. 9783642384042, Springer-Verlag Berlin Heidelberg, pp. 171-188. https://doi.org/10.1007/978-3-642-38404-2_8
Griffiths E, Momparler RL, Karpf AR. Pharmacodynamic responses to DNA methyltransferase inhibition. In Epigenetic Therapy of Cancer: Preclinical Models and Treatment Approaches. Vol. 9783642384042. Springer-Verlag Berlin Heidelberg. 2014. p. 171-188 https://doi.org/10.1007/978-3-642-38404-2_8
Griffiths, Elizabeth ; Momparler, Richard L. ; Karpf, Adam R. / Pharmacodynamic responses to DNA methyltransferase inhibition. Epigenetic Therapy of Cancer: Preclinical Models and Treatment Approaches. Vol. 9783642384042 Springer-Verlag Berlin Heidelberg, 2014. pp. 171-188
@inbook{a707eda4efc54509bb0b83c7ed68cfa5,
title = "Pharmacodynamic responses to DNA methyltransferase inhibition",
abstract = "The DNA methyltransferase inhibitors, 5-azacytidine and decitabine, were initially developed at high dose for clinical use as classical cytotoxic agents and only later reidentified as epigenetically active drugs capable of reexpressing genes silenced by DNA methylation. Their clinical activity in myeloid malignancy has resulted in rapid acceptance into clinical practice for the treatment of patients with MDS and AML, a group of patients for whom other treatment strategies have been largely ineffective. Despite widespread clinical use in these patients, the mechanisms responsible for their efficacy remain opaque, and controversy remains regarding the relative contributions of demethylation of silenced tumor suppressor genes with induction of apoptosis and differentiation, induction of CG antigens expression with resultant antitumor immunity, and DNA damage events.",
author = "Elizabeth Griffiths and Momparler, {Richard L.} and Karpf, {Adam R}",
year = "2014",
month = "4",
day = "1",
doi = "10.1007/978-3-642-38404-2_8",
language = "English (US)",
isbn = "364238403X",
volume = "9783642384042",
pages = "171--188",
booktitle = "Epigenetic Therapy of Cancer",
publisher = "Springer-Verlag Berlin Heidelberg",

}

TY - CHAP

T1 - Pharmacodynamic responses to DNA methyltransferase inhibition

AU - Griffiths, Elizabeth

AU - Momparler, Richard L.

AU - Karpf, Adam R

PY - 2014/4/1

Y1 - 2014/4/1

N2 - The DNA methyltransferase inhibitors, 5-azacytidine and decitabine, were initially developed at high dose for clinical use as classical cytotoxic agents and only later reidentified as epigenetically active drugs capable of reexpressing genes silenced by DNA methylation. Their clinical activity in myeloid malignancy has resulted in rapid acceptance into clinical practice for the treatment of patients with MDS and AML, a group of patients for whom other treatment strategies have been largely ineffective. Despite widespread clinical use in these patients, the mechanisms responsible for their efficacy remain opaque, and controversy remains regarding the relative contributions of demethylation of silenced tumor suppressor genes with induction of apoptosis and differentiation, induction of CG antigens expression with resultant antitumor immunity, and DNA damage events.

AB - The DNA methyltransferase inhibitors, 5-azacytidine and decitabine, were initially developed at high dose for clinical use as classical cytotoxic agents and only later reidentified as epigenetically active drugs capable of reexpressing genes silenced by DNA methylation. Their clinical activity in myeloid malignancy has resulted in rapid acceptance into clinical practice for the treatment of patients with MDS and AML, a group of patients for whom other treatment strategies have been largely ineffective. Despite widespread clinical use in these patients, the mechanisms responsible for their efficacy remain opaque, and controversy remains regarding the relative contributions of demethylation of silenced tumor suppressor genes with induction of apoptosis and differentiation, induction of CG antigens expression with resultant antitumor immunity, and DNA damage events.

UR - http://www.scopus.com/inward/record.url?scp=84949178876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949178876&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-38404-2_8

DO - 10.1007/978-3-642-38404-2_8

M3 - Chapter

AN - SCOPUS:84949178876

SN - 364238403X

SN - 9783642384035

VL - 9783642384042

SP - 171

EP - 188

BT - Epigenetic Therapy of Cancer

PB - Springer-Verlag Berlin Heidelberg

ER -